This trial is evaluating whether Daratumumab / Hyaluronidase Injection will improve 2 primary outcomes, 2 secondary outcomes, and 2 other outcomes in patients with Hemolytic Anemia. Measurement will happen over the course of Up to 6 weeks.
This trial requires 10 total participants across 1 different treatment group
This trial involves a single treatment. Daratumumab / Hyaluronidase Injection is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Hemolytic anemia is commonly treated with intravenous, intramuscular, subcutaneous, or oral blood transfusions. Treatment of hemoglobinuria and transfusion reactions can be challenging; for example, the use of immunoglobulin treatments may be life-saving. Further research to identify and develop treatment methods that target all three steps of hemolysis pathogenesis is needed." - Anonymous Online Contributor
"A hemolysis is blood loss that starts in a blood vessel, and that causes damage to the red blood cells. Hemolytic anemia can be congenital, acquired, or traumatic. Congenital hemolytic anemia occurs only when a person is born with a genetic predisposition to it such as sickle cell aplasia. The most common cause of acquired hemolytic anemia is medication. Hemolytic anemia is most commonly defined as a sudden decrease in red blood cell production caused by damage to the bone marrow." - Anonymous Online Contributor
"The annual number of people in the United States who develop hemorrhagic symptoms from an erythrocytic hemolytic process is estimated to be 1.4 per 10,000 population per year. This incidence is about 2-fold higher than that seen in Europe and North America." - Anonymous Online Contributor
"The majority of patients with a history of hemolytic anemia of long duration were cured of Hb<5 g/dL. The success rate of the procedure in treating Hb<5 g/dL is lower when it is performed more advanced in life expectancy." - Anonymous Online Contributor
"Signs of anemia include pallor, tachypnea, dyspnea, and jaundice. These signs are also found in patients without hemolytic anemia. Hemolytic anemia can be confirmed by a complete peripheral blood smear, though a bone marrow examination can also be done.\n" - Anonymous Online Contributor
"Most cases of hemolytic anemia are of low or intermediate risk, but some are of high risk and may require prompt consultation with a hematologist. The diagnosis and management of anemia must be based on the underlying mechanism of the disease." - Anonymous Online Contributor
"[Hemolytic anemia may result from a variety of causes (see Causes of anemia). Nevertheless, in more than 95% of cases an identifiable cause is identified, which can be managed to prevent further anemia manifestations and/or morbidity and mortality. For the next decade, transfusion of blood components will depend on the anemia cause, as it has been with all previous forms of transfusion (blood components were introduced into the use of anemia management in 1952 in the United States). Transfusion therapy is based on the "RBC" or red blood cell, which cannot be replaced by blood components, as in the case of hemolysis (loses its ability to donate blood)." - Anonymous Online Contributor
"Dara-Mab / HA is generally associated with the possibility of a life-threatening anaphylactic reaction. Such a reaction occurs if daratumumab is used in combination with a broad range of agents." - Anonymous Online Contributor
"DMT seems to be useful to reduce IAEs in refractory cases of IBD. However, the mechanism for the effect of DMT in inducing IAEs is unknown. One possible explanation that could be given is that DMT may induce IAEs primarily because of hyaluronidase effect and that the effects should not be considered the primary effect of DMT. Since IAEs were reduced in some cases in this group, DMT may be a potential treatment for other autoimmune diseases (e.g. rheumatoid arthritis)." - Anonymous Online Contributor
"We suggest that daratumumab should not be prescribed intravenously, but should be administered subcutaneously; however, since the effectiveness of this method is not clear, we suggest that it should be prescribed for a limited number of patients. Further development of treatments for rIT is necessary." - Anonymous Online Contributor
"Even in the absence of acute inflammation of the perisinus sulcus, hemolysis can be severe and prolonged. Patients should be monitored carefully whilst hospitalized, on dialysis and throughout their recovery period after the operation." - Anonymous Online Contributor
"Despite the small number of people included and the short duration of follow-up it seems that the daratumumab/hyaluronidase injection would not have a profound effect on hematologic parameters during the follow-up period. So it is safe to administer this therapy for 5 months in healthy adults." - Anonymous Online Contributor